Branded

MONTREAL — Canadian drug maker Valeant Pharmaceuticals International is buying Medicis Pharmaceutical for $2.6 billion, Valeant said Monday.

The $44-per-share deal, which the companies said represents a 39% premium over the closing price of Medicis' shares on Friday, is expected to close in the first half of 2013.

INDIANPOLIS — Lilly Diabetes announced that it has launched a new mobile application designed for caregivers and healthcare providers who support people with Type 1 diabetes.

The Lilly Glucagon mobile app is an interactive tool designed to teach caregivers how to use severe hypoglycemia treatment Glucagon (1-mg) for injection through simulated practice, thus helping caregivers better understand Glucagon's role in diabetes management. The Lilly Glucagon mobile app includes:

• Information about severe hypoglycemia and Glucagon;

SILVER SPRING, Md. — The Food and Drug Administration has approved a new formulation of a cancer drug made by Novartis for a type of brain tumor in children, the agency said.

The FDA announced the approval of Afinitor Disperz (everolimus) tablets for oral suspension to treat a rare brain tumor called subependymal giant-cell astrocytoma, or SEGA. The agency said Afinitor Disperz, a new dosage form of the drug Afinitor, is the first pediatric-specific dosage form for a pediatric tumor to receive FDA approval.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Astellas Pharma U.S. and Medivation for treating prostate cancer, the agency said Friday.

The FDA announced the approval of Xtandi (enzalutamide) for castration-resistant prostate cancer that has spread or recurred despite medical or surgical therapy to minimize testosterone.

WASHINGTON — The National Council on Aging last week introduced a new national Flu + You campaign to improve vaccination rates among seniors.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating bowel diseases made by Ironwood Pharmaceuticals, the agency said Thursday.

INDIANAPOLIS — Eli Lilly announced that Michael Harrington will be promoted to SVP and general counsel, effective Jan. 1, 2013.

Harrington — who currently serves as VP and deputy general counsel for the drug maker and is responsible for the legal function across Lilly's five business units — will replace Robert Armitage, who will retire at the end of the year. In his new role, Harrington will report to Lilly chairman, president and CEO John Lechleiter and will serve on the company's executive committee.

INDIANAPOLIS — Drug maker Eli Lilly has partnered with nationally recognized health literacy experts to implement new standards to ensure the company's patient communications and resources adhere to health literacy principles.